BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38110887)

  • 21. Options for screening for colorectal cancer.
    Atkin W
    Scand J Gastroenterol Suppl; 2003; (237):13-6. PubMed ID: 12797674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
    Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
    Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing.
    Wong CK; Lam CL; Wan YF; Fong DY
    BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of continued mailed fecal tests in the patient-centered medical home: Year 3 of the Systems of Support to Increase Colon Cancer Screening and Follow-Up randomized trial.
    Green BB; Anderson ML; Chubak J; Fuller S; Meenan RT; Vernon SW
    Cancer; 2016 Jan; 122(2):312-21. PubMed ID: 26488332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accuracy of self-checked fecal occult blood testing for colorectal cancer in Thai patients.
    Lohsiriwat V
    Asian Pac J Cancer Prev; 2014; 15(18):7981-4. PubMed ID: 25292099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Compliance rate of screening colonoscopy and its associated factors among high-risk populations of colorectal cancer in urban China].
    Chen HD; Li N; Ren JS; Shi JF; Zhang YM; Zou SM; Zheng ZX; Zhang K; Dai M
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Mar; 52(3):231-237. PubMed ID: 29973000
    [No Abstract]   [Full Text] [Related]  

  • 27. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in colorectal cancer screening with home-based fecal occult blood tests in adults ages 50 to 64 years, 2000-2008.
    Bandi P; Cokkinides V; Smith RA; Jemal A
    Cancer; 2012 Oct; 118(20):5092-9. PubMed ID: 22434529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.
    Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in colorectal cancer screening use after introduction of alternative screening offer in Germany: Prospective cohort study.
    Guo F; Chen C; Schöttker B; Holleczek B; Hoffmeister M; Brenner H
    Int J Cancer; 2020 May; 146(9):2423-2432. PubMed ID: 31291471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States.
    Singal AG; Corley DA; Kamineni A; Garcia M; Zheng Y; Doria-Rose PV; Quinn VP; Jensen CD; Chubak J; Tiro J; Doubeni CA; Ghai NR; Skinner CS; Wernli K; Halm EA
    Am J Gastroenterol; 2018 May; 113(5):746-754. PubMed ID: 29487413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial.
    Gupta S; Halm EA; Rockey DC; Hammons M; Koch M; Carter E; Valdez L; Tong L; Ahn C; Kashner M; Argenbright K; Tiro J; Geng Z; Pruitt S; Skinner CS
    JAMA Intern Med; 2013 Oct; 173(18):1725-32. PubMed ID: 23921906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ontario's ColonCancerCheck: results from canada's first province-wide colorectal cancer screening program.
    Rabeneck L; Tinmouth JM; Paszat LF; Baxter NN; Marrett LD; Ruco A; Lewis N; Gao J
    Cancer Epidemiol Biomarkers Prev; 2014 Mar; 23(3):508-15. PubMed ID: 24443406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colonoscopy and fecal occult blood test use in Germany: results from a large insurance-based cohort.
    Stock C; Ihle P; Schubert I; Brenner H
    Endoscopy; 2011 Sep; 43(9):771-81. PubMed ID: 21830189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
    Deutekom M; van Rossum LG; van Rijn AF; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
    Scand J Gastroenterol; 2010 Nov; 45(11):1345-9. PubMed ID: 20560814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The public prefers fecal occult blood test over colonoscopy for colorectal cancer screening.
    Almog R; Ezra G; Lavi I; Rennert G; Hagoel L
    Eur J Cancer Prev; 2008 Oct; 17(5):430-7. PubMed ID: 18714185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Screening for colorectal cancer in high-risk and intermediate-risk subject: what's the best tool?].
    Trevisani L; Cifalà V; Sartori S; Tombesi P; Matarese V; Pezzoli A; Abbasciano V
    Recenti Prog Med; 2009 Feb; 100(2):68-72. PubMed ID: 19350797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Screening for colorectal cancer using immunological fecal occult blood test in inpatients].
    Kawabata H; Inoue N; Kawakatsu Y; Okazaki Y; Hitomi M; Miyata M; Motoi S
    Nihon Shokakibyo Gakkai Zasshi; 2018; 115(4):377-384. PubMed ID: 29643290
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.